Many clinical trials have demonstrated that EGFR TKIs have an excellent clinical survival benefit in advanced NSCLC patients, although traditional cytotoxic chemotherapy still plays an important role in the treatment of NSCLC8, 9, 10. This evidence concerns the gene EGFR and non-small cell lung carcinoma.